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Abstract
Background: Restenosis remains to be a major limitation of percutaneous transluminal angioplasty (PTA) for diabetic
patients with peripheral vascular disease (PVD). Despite of stations routine implements to prevent such progress, its
exact effect is unclear.
Methods and results: In our study, balloon was successfully implanted in the iliac artery of atherosclerotic rabbit.
Patency of the narrowed artery was interrogated using ultrasound. Atorvastatin or vehicle was administered orally
to rabbits from day 0 to day 28 after double-injury surgery. On day 7, day 14, and day 28, restenotic arteries were
harvested and processed for histopathlogical analysis. Our data show that, after double-injury surgery, the intima
was composed mostly by SMCs at all time course in rabbits undergoing surgery process. Significant increases in
stenosis rates were noted from day 7 to day 14 (from 21 ± 5.85 % to 60.93 ± 12.46 %). On day 28 after double-injury
surgery, severe restenosis was observed and daily administration of atorvastatin cannot prevent restenosis’ formation
(88.69 ± 3.71 % vs. 90.02 ± 3.11 %, P > 0.05). The PCNA index and SMCs proliferation were correlated with the scores of
the vascular pathology.
Conclusions: Our results indicate that double-injury model can mimic clinical restenosis, based on this model,
atorvastatin showed no therapeutic effect on restenosis process in diabetic rabbits after PTA.
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Background
Percutaneous transluminal angioplasty (PTA), despite its
widespread use and high initial success rate in diabetes
mellitus with peripheral vascular disease (PVD) [1], re-
stenosis, which occurs in up to 70 % patients within one
year [2] becomes the limitation for this clinical applica-
tion. Attempting to pharmacological prevent or reduce it
by using antiplatelet agents, corticosteroids, and calcium
channel blockers have been unfavorable [3].
Lack of practical restenosis model has limited the pos-
sibility to investigate potential therapies. Mounting
angioplasty-stenosis animal models have been employed
to investigate the pharmacological and mechanical ap-
proaches. However, in most studies [4, 5], overstretching
angioplasty balloons on normal arteries were developed
to reproduce aspects of the human vascular response to
PTA (single-injury model) which is applied to build ath-
erosclerosis models, not restenosis models. Therefore, it
is crucial to set up a reliable animal model to obtain the
ability of investigating the potential therapies to prevent
restenosis after PVD patients undergoing PTA.
Statins, a class of 3-hydroxy-3-methylglutaryl (HMG)-
coenzyme A (CoA) reductase inhibitors, have both anti-
inflammatory and anti-proliferative properties irrespective
of their cholesterol-lowering effects [6]. Data from previ-
ous studies showed that statins reduced both inflamma-
tory responses [7] and neointimal hyperplasia of arteries
in balloon injury animal models (single-injury animal
models) [8]. For these reasons, it is clinically used as a
routine treatment for PVD patients undergoing PTA to
inhibit the process of restenosis. However, in our daily
work, we found the clinical efficacy of statins for the
restenosis inhibition was minor.
In the present study, we established a double-injury
restenosis model in New Zealand white rabbits that
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mimic the proliferative process of human iliac artery
restenosis after PTA with hyperglycemia. Atorvastatin
is the most widely prescribed statin drug [9]. Thus, in
this study, atorvastatin was used to test how much
the administration of statins could contribute to the
inhibition of restenosis. By using this animal model,
we aimed to investigate the potential therapies of re-
stenosis after PTA in diabetes patients with PVD, or




This experiment was approved by the Chinese National
Institutes of Health, and the protocol was approved by
the ethical committee of Qianfoshan Hospital Affili-
ated to Shandong University. Male New Zealand white
rabbits (1.7 kg) were obtained from the Animal Center
of Shandong Agriculture Science Academy, China. The
rabbits were singly housed in standard rabbit caging
and maintained on a 12:12-h light: dark cycle. Athero-
genic diet (1 % cholesterol) was given to rabbits 1 week
before the experimentation until sacrificed. All rabbits
had free access to water throughout the duration of
the study.
Experimental protocol
Induction of experimental diabetes mellitus: after an
overnight fasting, 80 mg/kg of freshly prepared alloxan
solution was injected intravenously from the marginal
ear vein of rabbits [10]. Animals had free access to
food and water after the alloxan injection, and an oral
solution of 20 % glucose was provided after confirm-
ation of hypoglycemia to prevent hypoglycemic shock.
Blood glucose concentrations were measured one week
after alloxan injection, animals with blood glucose levels
>300 mg/dl were considered as diabetic and enrolled in
the experiment.
Double-injury surgical procedure: (1) Balloon-induced
endothelial injury surgery was performed to induce ath-
erosclerotic plaque. One week after diabetes induction,
rabbits were anesthetized with phenobarbital. An arter-
iotomy in the right saphenous artery was made with
standard surgical techniques, then a 2.5-mm, wire-
guided balloon catheter was inserted and the iliac artery
injury was made as previously described [10] (Fig. 1a).
The iliac artery developed severe atherosclerotic damage
at about 4 weeks after the first surgical procedure,
confirmed by ultrasound examination (Visualsonics,
Toronto, Canada) (Fig. 1b). (2) PTA was then performed
to induce restenotic plaque. Balloon catheter was
inserted into the previously balloon-injured iliac artery
through the dissected distal ends of the right femoral
artery, and PTA was performed at the first injury site
(Fig. 1c). Following the above treatment, another color
Doppler was developed to demonstrate the patency of
the atherosclerotic iliac arteries (Fig. 1i).
Restenosis models successfully induced by double-
injury surgery were divided into four groups: 7-day re-
stenosis group (group 1, n = 6); 14-day restenosis group
(group 2, n = 6); 28-day restenosis group (group 3, n = 6)
and 28-day atorvastatin group (group A, n = 6). The
atorvastatin dosages (2.5 mg/kg/d)) were determined by
previous studies [11, 12]. Atorvastatin therapy started on
the day of double-injury surgery and was administered
orally by gastric gavage. Six sham-operated diabetic rab-
bits underwent the same surgical procedure, except that
the balloon was not inserted and were applied to the
control group (group C).
Tissue harvest and morphometric analysis
At each time points (7, 14, and 28 days after double-injury
surgery), animals were sacrificed (animals in group A and
group C were sacrificed on day 28). Blood samples were
collected from the ear vain and the levels of serum total
cholesterol, triglycerides, low-density lipoprotein, and
high-density lipoprotein cholesterol were detected. The
injured iliac artery segments were fixed in in 4 % formal-
dehyde, embedded in paraffin. 5 μm sections were stained
with hematoxylin-eosin (HE) for general appearance,
Masson’s trichrome for collagen and smooth muscle cells
(SMCs), and elastic van-Gieson (EVG) dye for elastin,
then observed under microscopy (OLYMPUS FSX100).
Morphometric analysis of the intimal growth was per-
formed by the image analysis software Image Pro-Plus
Software (Image Pro-Plus 6.0, Media Cybernetics, Silver
Spring, MD, USA). Intimal growth was estimated by the
ratio of the intimal area to the area bounded by the
internal elastic lamina (luminal cross-sectional area nar-
rowing) and the ratio of intimal to medial areas [13, 14].
Immunohistochemical analysis
Paraffin embedded sections were deparaffinised with
Histoclear and rehydrated through graded ethanols. Heat
induced antigen retrieval was performed in a microwave
oven using Tris-EDTA buffer (10 mM Tris, 1 mM
EDTA, 0.05 % Tween 20, pH 9.0) for 20 min and the
slides were allowed to cool down prior to blocking with
3 % H2O2. After blocking with 5 % (v/v) goat serum in
phosphate buffered saline (PBS), sections were incubated
overnight at 4 °C with the primary antibodies. After a PBS
wash, the sections were incubated with secondary antibody
at 37 °C for 30 min. Visualization of a positive reaction was
by means of a peroxidase substrate solution containing
0.02 % (wt/Vol) H2O2 and 0.1 % (wt/Vol) 3,3′-diaminoben-
zidine tetrahydrochloride (ZSBIO, Beijing, China) in PBS
to produce a brown color, then the sections were counter-
stained with hematoxylin. A negative control, with the
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primary antibody replaced by mouse IgG antibody, was
always included. The primary antibodies used were anti-
proliferating cell nuclear antigen antibody (PCNA) (Merck,
Millipore, Darmstadt, Germany) diluted 1:400 to identify
cell proliferation. PCNA positive cells were counted in 10
randomly selected × 200 high-power fields under a micro-
scope (OLYMPUS FSX100). The PCNA index was calcu-
lated according to the following formula: number of
PCNA positive cells/total cell count × 100 % [15].
Immunofluorescent staining
Immunofluorescent staining was performed. Briefly, en-
dogenous peroxidase activity was inhibited by incubation
with 3 % H2O2 and blocked with 5 % (v/v) goat serum
for 1 h. After washing with PBS, slides were incubated
with FITC conjugated-smooth muscle actin antibody
(αSMA) (1:100; Abcam, Cambridge, United Kingdom) for
four hours. A second wash was followed by preparation
of slides in DAPI-Fluoromount-G. Specimens were
examined with a fluorescence microscope (OLYMPUS
FSX100).
Statistical analysis
All data are presented as mean ± standard Error (SE). Com-
parisons were made using one-way ANOVA with SPSS
Software (Version 20.0, SPSS China, Shanghai, China). A
value of P < 0.05 was considered statistically significant.
Results
Animals
At the beginning, 45 New Zealand white rabbits were
enrolled. After injected with alloxan, 30 generated hyper-
glycemia successfully, five died and ten were excluded
due to inadequate glucose levels. Of the 30 established
diabetic rabbits, 24 received double-injury surgery, and
all achieved restenosis.
Fig. 1 a The distal saphenous artery was ligated and a balloon catheter (BC) was advanced into the femoral and iliac arteries through an arteriotomy
(Art) in the proximal saphenous artery. b Atherosclerotic plaque (AS) was established in the femoral and iliac arteries. c After the first surgery,
a midsagittal incision was made in the dissected distal ends of the femoral artery. A BC was inserted into the narrowed artery and inflated at
the site of stenosis. d After the double-injury surgery, restenotic plaque (RS) was established in the post-PTA artery. e and f Bright field view of
control and restenosis arteries, respectively. g Color Doppler demonstrated blood flow through non-injured arteries. h Color Doppler demonstrated
the atherosclerotic plaque’s formation in iliac arteries after the first balloon injury. i Color Doppler demonstrated the patency of the stenosed
iliac arteries after PTA surgery
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The body weights and blood glucose levels of the dia-
betic rabbits were measured. Blood glucose concentra-
tions were maintained at levels higher than 300 mg/dl
throughout the study. On day 28, the serum total choles-
terol level was 18.75 ± 0.44 mmol/l in group C, 18.47 ±
0.54 mmol/l in group 3, and 9.44 ± 0.27 mmol/l in group
A. There was no significant difference in the serum total
cholesterol level between the group C and group 3, a
significant decrease was found between group A and
group 3 (P < 0.05). Similar findings were observed for
the serum LDL-cholesterol level (10.2 ± 0.35 mmol/l in
group C, 10 ± 0.34 mmol/l in group 3, and 4.60 ±
0.18 mmol/l in group A), and the serum triglycerides
level (2.01 ± 0.04 mmol/l in group C, 2.15 ± 0.05 mmol/l
in group 3, and 1.36 ± 0.05 mmol/l in group A). No sig-
nificant difference of serum HDL-cholesterol levels were
found among these groups (0.86 ± 0.02 mmol/l in group
C, 0.81 ± 0.03 mmol/l in group 3, and 0.88 ± 0.02 mmol/l
in group A). Details were shown in Table 1.
Histopathological study and time course of the double-
injury model
The intimal thickening that formed after the primary
injury contained SMCs embedded in matrix and served
as the substrate for the PTA (Fig. 2a). After the double-
injury surgery, there was obvious evidence of trauma,
including extensive breaks in the internal elastic laminae
and intimal dissections extending into the media.
In the protocol on the time-course of restenosis for-
mation, we used 18 rabbits (6 each for 3 time points
after double-injury surgery) to observe the restenosis
process. Figure 2a shows that there was a progressive
increase in the intima of the iliac arteries of rabbits that
underwent double-injury surgery, compared to the iliac
arteries of rabbits in group C (P < 0.05). The stenosis
rate increased from 21 ± 5.85 % to 60.93 ± 12.46 %
and 90.02 ± 3.11 % at day 7, 14, 28, respectively
(Fig. 2b). Similarly, intima/media ratio increased from
0.35 ± 0.05 to 1.63 ± 0.29 at day 14 and 1.86 ± 0.14 at
day 28 (Fig. 2c).
Expression of PCNA was maximally induced at seven
days (49.88 ± 4.55 %), then decreased to 38.98 ± 2.32 %
on day 14 and stay still on day 28 (Fig. 3). By immuno-
histochemistry of alpha-actin (a marker for SMCs), it
showed that at each time point, the intima was almost
entirely contained by SMCs (Fig. 4).
Effects of atorvastatin on stenosis rate and the intima/
media areas in the double-injury model
Twenty eight days atorvastatin treatment in group A,
didn’t reduce the increased stenosis rate of the injured
iliac arteries of rabbits that underwent double-injury sur-
gery (P > 0.05, Fig. 2b). In keeping with the stenosis rate
results, the calculated intima/media ratio was signifi-
cantly increased in group 3, but atrovasatin treatment
didn’t reduce the increased intima/media ratio in group
A (Fig. 2c).
Effect of atorvastatin on cell proliferation and SMCs
migration
To further elucidate atorvastatin’ effect acts on re-
stenosis in the double-injury model, we performed
immunostainings for PCNA for the conditions of cell
proliferation and Masson as well as αSMA immuno-
fluorescence stainings for SMCs migration in the neo-
intima. The PCNA index in the injured iliac artery of
rabbit in group 3 was significantly increased (P < 0.05,
Fig. 3). After atorvastatin treatment, the PCNA index
remained high and unchanged compared to group A
(P > 0.05, Fig. 3). As revealed by alpha-actin immunohisto-
chemistry, in samples from both atorvastatin treatment
(group A) and non-atorvastatin treatment (group 3)
groups, large number of SMCs were observed in the
intima, and no significant difference was found between
these two groups (P > 0.05, Fig. 4).
Discussion
For many years, efforts to prevent restenosis have
been unsuccessful because of the poor understanding
of its pathophysiological mechanism [3]. The lack of
the ideal restenosis animal model is the major obs-
tacle. Although the single-injury animal model has
made important contributions to understanding the
mechanisms underlying restenosis [4, 5, 16], it may
Table 1 Animal characteristics
New Zealand Group C Group 1 Group 2 Group 3 Group A
White rabbits (n = 6) (n = 6) (n = 6) (n = 6) (n = 6)
Weight (kg) 2.16 ± 0.27 2.04 ± 0.19 2.17 ± 0.31 2.25 ± 0.22 2.30 ± 0.33
Glucose (mmol/l) 19.71 ± 0.92 20.18 ± 0.93 19.95 ± 1.02 19.65 ± 1.18 19.73 ± 0.87
Total cholesterol (mmol/l) 18.75 ± 0.44 18.61 ± 0.48 18.68 ± 0.38 18.47 ± 0.54 9.44 ± 0.27*
LDL-cholesterol (mmol/l) 10.2 ± 0.35 10.3 ± 0.30 10.2 ± 0.48 10 ± 0.34 4.60 ± 0.18*
Serum triglycerides (mmol/l) 2.01 ± 0.04 2.08 ± 0.04 2.05 ± 0.04 2.15 ± 0.05 1.36 ± 0.05*
HDL-cholesterol (mmol/l) 0.86 ± 0.02 0.80 ± 0.02 0.81 ± 0.02 0.81 ± 0.03 0.88 ± 0.02
*P < 0.05 vs Group 3
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Fig. 2 Restenosis’s formation in iliac arteries after double-injury surgery. HE and VGF-stained sections show increasing neointimal formation post
double-injury surgery at 7, 14 and 28 days compared to sham-operated controls (Group C). Atorvastatin’s inhibitory effect on restenosis was examed as
well (Group A). a Restenosis was measured by the total size of the artery. b The stenosis rate. c The inimal-to-media area ratio. * P < 0.05
vs. group N; # P < 0.05 vs. 7-day; + P < 0.05 vs. 28-day
Fig. 3 PCNA expression in the double-injury iliac arteries. Magnification 200×. Quantification of positive immunostaining expressed as a ratio of
positive/total cells ± standard Error. * P < 0.05 vs. group N; # P < 0.05 vs. 7-day; + P < 0.05 vs. 28-day
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not reflect the events occurring in atherosclerotic ar-
teries that are treated with balloon angioplasty and
subsequently become renarrow.
Histopathologic observation of restenotic tissue from
living patients has become readily available with the ad-
vent of directional atherectomy [17, 18]. Our double-
injury restenosis rabbit model was generated by inducing
atherosclerotic plaques in the iliac artery and then
deployed PTA on the atherosclerotic rabbits. The histo-
pathology in the restenosis rabbit model mimics human
artery restenosis well, including proliferation and mi-
gration of SMCs in the restenosis segment which have
been identified as the most important histopathological
changes in human restenosis, and a similar percentage
of proliferating cell in restenotic plaque. Thus, this animal
model may provide a pathologic correlation to the human
retenosis after PTA treatment and would provide a plat-
form for evaluating anti-restenotic drugs and may carry
out basic studies to determine the molecular mechanisms
underlying the post-PTA neointimal formation.
The time-course of restenosis was examed in our
study. We found that restenotic plaque initiated to
form from day 0 to day 7, but developed more rap-
idly from day 7 to day 14 and this tendency contin-
ued to day 28. Previous studies have shown that the
migration of SMCs from the tunica media towards
the intima which is thought to be a key event in the
neointimal formation in restenosis was initiated by
balloon injury with a switch of contractile phenotype
[19, 20]. This change of phenotype occurred at about
one week after the arterial injury [21]. And that may
be the reason for the fastest formation of restenotic
plaque starting at day 7.
What’s interesting is that the data in our study showed
atorvastatin treatment had no effect on the inhibition of
SMCs proliferation and migration in the injured iliac ar-
tery of resenosis rabbit models, therefore cannot prevent
neointimal formation after PTA. This is consistent with
our clinical observation.
In fact, some better-controlled clinical trials have made
a point that statins lacked therapeutic efficacy on resten-
osis inhibition. And as the most widely prescribed statin
drugs [22–25], atorvastatin cannot arrest the develop-
ment of restenosis in our study, despite it also has effect
on the inhibition of SMCs’ proliferation and migration
in vitro [26, 27]. There could be several explanations for
the discrepancies of atorvastatin’s effect on restenosis
between in vitro and in vivo results. Firstly, experimental
exposure of isolated SMCs to atorvastatin in the culture
medium may be quite different from in vivo situation,
especially that the proliferation and migration of SMCs
after PTA is initiated from depth within the arterial
media. Therefore, it is possible that the target atorvasta-
tin’s pinpoint has little contribution to the restenosis
progress in vivo. Secondly, in vivo, conditions are more
complex than those in vitro, different factors and signal
pathways may be involved in the pathogenesis of resten-
osis. Atorvastatin may inhibit some factors or pathways
relevant with restenosis inhibition [26, 27], but it is quite
possible that other restenosis promoting factors or
pathways counterbalance atorvastatin’s effect. Then the
net result is atorvastatin cannot significantly inhibit the
Fig. 4 Masson and αSMA immunofluorescence stainings for SMCs in the double-injury iliac arteries. Representative sections are shown. Magnification
40× and 200×
Zhou et al. BMC Cardiovascular Disorders  (2016) 16:153 Page 6 of 8
development of restenosis in vivo. Thirdly, phenotype
switch of SMCs results in SMCs’ proliferation and
migration cannot be inhibited by atorvastatin.
To our knowledge, this is the first report of the animal
restenosis model by using double-injure surgery and
investigation of the effect of atorvastatin. This model
may support further investigation of the pathophysio-
logical mechanisms underlying restenosis after PTA and
research for seeking effective therapeutic interventions.
This study reports preliminary data. Our investigation
did not evaluate the fate of the restenosis after PTA at
time points greater than 28 days as we were interested
in the rapid mimicking ability of restenosis after PTA in
animal models. Since the timeline for restenosis of our
animal model was significantly shorter than that of human
restenosis after PTA, this model had less collaterals.
Conclusion
In conclusion, we could reproducibly develop restenosis
in animal peripheral arteries that mimic human restenosis
after PTA. This model may be beneficial for elucidating
restenosis mechanisms and seeking for therapeutic inter-
ventions. Atorvastatin was demonstrated to have no thera-
peutic effect on the inhibition of restenosis process.
Further studies should be carried out to search for more
efficient therapies.
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